0001140361-24-008357.txt : 20240216
0001140361-24-008357.hdr.sgml : 20240216
20240216160543
ACCESSION NUMBER: 0001140361-24-008357
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Militello John
CENTRAL INDEX KEY: 0001662170
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 24648324
MAIL ADDRESS:
STREET 1: C/O IMMUNE PHARMACEUTICALS INC.
STREET 2: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
FORM 4
X0508
4
2024-02-14
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001662170
Militello John
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
See Remarks
false
Common Stock
2024-02-14
4
M
0
6274
0
A
16433
D
Restricted Stock Units
2024-02-14
4
M
0
725
0
D
Common Stock
725
2903
D
Restricted Stock Units
2024-02-14
4
M
0
5549
0
D
Common Stock
5549
10159
D
Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
VP, Principal Accounting Officer and Interim Principal Financial Officer
/s/ Martin Wilson, as attorney-in-fact for John Militello
2024-02-16